Abemaciclib compared with placebo for newly diagnosed grade 3 meningioma
Tests abemaciclib against placebo in adults newly diagnosed with grade 3 meningioma.
Key facts
- Who runs it
- Nader Sanai
- Where
- Phoenix, United StatesSee the site
- Trial code
- Registry title
- Abemaciclib in Newly Diagnosed Meningioma Patients
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 72 people, planned
- Started
- 24 Mar 2025
- Expected to end
- Sept 2030
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Abemaciclib
- Placebo
- Record updated
- 13 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a newly diagnosed grade 3 meningioma, a brain tumor, whose tumor tissue tests positive for RB. They get abemaciclib or a placebo after standard radiation therapy.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Newly diagnosed WHO Grade 3 meningioma inside the skull, or a lower grade meningioma that has newly changed to Grade 3. People must be up and about at least half the day (ECOG 2 or less).
- Earlier treatment
- People must plan to have, or have had, standard radiation therapy for the Grade 3 meningioma. No other treatment for it before, except surgery or biopsy. If you had a lower grade meningioma before, only surgery or biopsy, and no radiation. No prior CDK4/6 inhibitor.
- Biomarker or test result
- Tumor tissue from surgery must test positive for RB (RB-proficient).
Main reasons for not taking part
- Pregnancy or breastfeeding
- Another cancer still being treated
- Active or uncontrolled serious infection, including known HIV, HBV or HCV
- Liver disease such as cirrhosis or active hepatitis
- Allergy to parts of abemaciclib
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Participants with newly diagnosed intracranial WHO Grade 3 meningioma; or,
- Participants with previous lower grade meningioma and histopathologically confirmed newly transformation to Grade 3
- Plan to receive or have received upfront standard of care radiation therapy (RT) for the newly diagnosed WHO Grade 3 meningioma
- No prior treatment for Grade 3 meningioma other than surgical resection or biopsy and upfront RT. If previously diagnosed with a lower grade meningioma, no prior treatment other than surgical resection or biopsy and no prior RT
- Ability to understand and the willingness to sign a written informed consent document (personally or by the legally authorized representative, if applicable)
- Participant has voluntarily agreed to participate by giving written informed consent (personally or via legally authorized representative[s], and assent, if applicable). Written informed consent for the protocol must be obtained prior to any screening procedures. If consent cannot be expressed in writing, it must be formally document and witnessed, ideally via an independent trusted witness. Participant must be willing and able to comply with scheduled visits, treatment plans, laboratory tests and other procedures
- Age ≥18 years at time of consent
- Have a performance status (PS) of ≤2 on the Eastern Cooperative Oncology Group (ECOG) scale
- Ability to swallow oral medications
- Participant has adequate bone marrow and organ function as defined by the following laboratory values (as assessed by the local laboratory for eligibility):; Adequate Bone Marrow Function: absolute neutrophil count ≥1,500/mcL, platelets ≥100,000/mcL, and hemoglobin ≥8.0 g/dL (individual may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator; initial treatment must no begin earlier than the day after any erythrocyte transfusion); Adequate Hepatic Function: total bilirubin ≤1.5x ULN (individuals with Gilbert's syndrome with a total bilirubin ≤2.0x ULN and direct bilirubin within normal limits are permitted), AST/SGOT ≤3x ULN, and ALT/SGPT ≤3x ULN
- Confirmed negative serum pregnancy test (β-hCG) before starting study treatment or participant who is no longer of childbearing potential due to surgical, chemical, or natural menopause
- For females of reproductive potential: use of highly effective contraception during study participation and for an additional 3 weeks after the end of treatment administration
- For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner and for an additional 3 weeks after the end of treatment administration
Who cannot take part
- Prior therapy with any CDK4/6 inhibitor. Prior therapy is defined as therapeutic dosing
- Treatment with another investigational drug within 5 half-lives of the investigational product
- Prior history of cancer with ongoing treatment of disease
- Known allergic reactions to components of the abemaciclib
- Active infection or fever >38.5°C requiring systemic antibiotic, antifungal or antiviral therapy within 4 weeks of Day 1
- Known to have active (acute or chronic) or uncontrolled severe infection, liver disease such as cirrhosis, decompensated liver disease, and active and chronic hepatitis
- Known active systemic bacterial infection (requiring IV antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known HIV positivity or with known HBV or HCV). Screening is not required for enrollment
- Participant has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study
- Pregnancy or breastfeeding
Where in United States
- St. Joseph's Hospital and Medical CenterPhoenix, United StatesContact: Phase 0 NavigatorTaking people
About the trial
What the trial wants to find out
This study is being done to learn about how an investigational drug called abemaciclib works in treating patients with a newly-diagnosed grade 3 meningioma. Abemaciclib is a drug that is approved by the FDA, but not for brain tumors.
Read full original descriptionShow less
Participants who consent to the trial will have surgical tissue collected from the planned surgical resection and tested. If the tissue shows positive results for RB cells and participants are qualified, they will be enrolled and receive study treatment two to five weeks after completing standard-of-care radiation therapy.
This is a randomized clinical trial which means that participants will be randomly assigned to a treatment based on chance, like a flip of a coin. Neither the participant nor the researcher chooses the assigned group. Randomization will help the researchers study how the drug works by comparing the difference between the study drug and the placebo and how they work in treating brain tumors. This is a double-blinded study, which means that neither the participant nor the study team will know which treatment the participant is receiving.
The 2 groups in the trial
- Active Treatment (Abemaciclib)Treatment being tested
Administered twice daily on days 1-28 of each 28-day cycle.
Treatment: Abemaciclib
- PlaceboPlacebo, for comparison
Administered twice daily on days 1-28 of each 28-day cycle.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Phase 2 Multicenter, Double-blind, Randomized-controlled Study of Abemaciclib (CDK4 and 6 Inhibitor) in Newly Diagnosed RB-proficient Grade 3 Meningioma Participants
- Plain-language title
- Abemaciclib compared with placebo for newly diagnosed grade 3 meningiomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 13 March 2026